Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Vanguard Health Systems, In
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Vanguard Health Systems, Inc. Shareholders
NEW YORK--(BUSINESS WIRE)-- Kirby McInerney LLP is investigating potential claims against the Board of Directors of Vanguard Health Systems, Inc. ("Vanguard" or the "Company") (NYS: VHS) related to the proposed acquisition of the Company by Tenet Healthcare Corporation ("Tenet") (NYS: THC) . Under the terms of the definitive agreement, Tenet will purchase all of the outstanding common stock of Vanguard for $21.00 per share in cash, for a total transaction value of approximately $4.3 billion including the assumption of $2.5 billion of Vanguard debt. The investigation concerns whether the Vanguard Board of Directors violated its fiduciary duties by agreeing to this transaction and whether the proposed $21.00 per share consideration adequately values Vanguard common shares.
If you are a Vanguard shareholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at email@example.com, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.
Kirby McInerney LL
J. Brandon Walker, Esq.
212-699-1145 or 888-529-4787
KEYWORDS: United States North America New York
The article Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Vanguard Health Systems, Inc. Shareholders originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.